Crispr Therapeutics Ag Stock Story
| CRSP Stock | USD 55.66 0.61 1.11% |
Slightly above 56% of all Crispr Therapeutics' retail investors are looking to take a long position. The analysis of the overall investor sentiment regarding Crispr Therapeutics AG suggests that some traders are interested. Crispr Therapeutics' investor sentiment overview provides quick insight into current market opportunities from investing in Crispr Therapeutics AG. The current market sentiment, together with Crispr Therapeutics' historical and current headlines, can help investors time the market. In addition, many technical investors use Crispr Therapeutics stock news signals to limit their universe of possible portfolio assets and to time the market correctly.
Crispr Therapeutics stock news, alerts, and headlines are usually related to its technical, predictive, social, and fundamental indicators. It can reflect on the current distribution of Crispr daily returns and investor perception about the current price of Crispr Therapeutics AG as well as its diversification or hedging effects on your existing portfolios.
Crispr |
Requested story not found. it has been either deleted or moved. View all stories for Crispr Therapeutics AG.
Crispr Therapeutics Latest Timeline
Crispr Therapeutics is listed for 55.66. The company reported the previous year's revenue of 370 M. Net Loss for the year was (153.61 M) with loss before overhead, payroll, taxes, and interest of (570.7 M).Check out Crispr Therapeutics Hype Analysis, Crispr Therapeutics Correlation and Crispr Therapeutics Performance. You can also try the Portfolio Backtesting module to avoid under-diversification and over-optimization by backtesting your portfolios.
Complementary Tools for Crispr Stock analysis
When running Crispr Therapeutics' price analysis, check to measure Crispr Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Crispr Therapeutics is operating at the current time. Most of Crispr Therapeutics' value examination focuses on studying past and present price action to predict the probability of Crispr Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Crispr Therapeutics' price. Additionally, you may evaluate how the addition of Crispr Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets |
Is Crispr Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Crispr Therapeutics. If investors know Crispr will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Crispr Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.94) | Revenue Per Share 4.686 | Quarterly Revenue Growth 33.5 K | Return On Assets (0.06) | Return On Equity (0.08) |
The market value of Crispr Therapeutics is measured differently than its book value, which is the value of Crispr that is recorded on the company's balance sheet. Investors also form their own opinion of Crispr Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Crispr Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Crispr Therapeutics' market value can be influenced by many factors that don't directly affect Crispr Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Crispr Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Crispr Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Crispr Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.